Physician profile
Payam Aghassi
NPI 1093704298
$95,583.65
in general payments reported to CMS, 2019-2025
44 companies · $2,536 in 2025
The $2,536 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,079 · 2020: $590 · 2021: $40K · 2022: $34K · 2023: $15K · 2024: $2,197 · 2025: $2,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $6,529 · Education: $128 · Travel and Lodging: $31.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,550.00 |
| Food and Beverage | $6,529.39 |
| Education | $127.60 |
| Travel and Lodging | $31.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $43,388.85 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $37,129.57 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $8,803.24 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $812.43 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Pulmonx Corporation | $655.67 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $514.89 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Takeda Pharmaceuticals U.S.A., INC. | $334.28 | 2021-2025 | Glassia, Takhzyro |
| Electromed, INC. | $333.47 | 2022-2025 | Smartvest |
| Genzyme Corporation | $324.83 | 2019-2025 | |
| United Therapeutics Corporation | $292.88 | 2019-2025 | Tyvaso |
| Harmony Biosciences LLC | $268.34 | 2020-2024 | Wakix |
| Inspire Medical Systems, INC. | $234.26 | 2021-2025 | Inspire |
| Axsome Therapeutics, INC. | $204.23 | 2023-2025 | Sunosi |
| Amgen INC. | $171.56 | 2023-2025 | Tezspire |
| Mallinckrodt Hospital Products INC. | $170.29 | 2023-2024 | Acthar |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $155.36 | 2019-2024 | |
| Pfizer INC. | $139.23 | 2019-2024 | |
| Insmed, INC. | $127.54 | 2020-2025 | Arikayce, Brinsupri |
| Sunovion Pharmaceuticals INC. | $119.91 | 2019-2020 | |
| Inogen, INC. | $108.64 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth, Inogen One G3 Oxygen Concentrator |
| E.R. Squibb & Sons, L.L.C. | $108.24 | 2022-2024 | Camzyos, Eliquis |
| Philips North America LLC | $108.08 | 2019-2025 | Vest Therapy Und |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Genentech USA, INC. | $91.18 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $90.66 | 2021-2022 | |
| Grifols USA, LLC | $78.50 | 2019-2025 | Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $69.35 | 2020-2021 | |
| Cmp Pharma, INC. | $69.07 | 2022-2023 | Tadliq, Liqrev, Atorvaliq |
| Mylan Specialty L.P. | $68.72 | 2019-2023 | Yupelri |
| Advanced Respiratory, INC | $68.72 | 2020-2021 | |
| Lilly USA, LLC | $68.28 | 2025 | Zepbound |
| Itamar Medical INC | $49.79 | 2022 | |
| Merck Sharp & Dohme LLC | $47.29 | 2019-2020 | |
| Baxter Healthcare | $39.50 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Ethicon INC. | $37.88 | 2021 | |
| Resmed Corp | $34.89 | 2023-2024 | |
| Abbvie INC. | $27.76 | 2021 | |
| Viatris Specialty LLC | $22.99 | 2025 | Yupelri |
| Allergan, INC. | $21.42 | 2020 | |
| Verona Pharma, INC. | $20.53 | 2025 | Ohtuvayre |
| Olympus America INC. | $19.54 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $18.21 | 2025 | Neffy |
| Shire North American Group INC | $16.99 | 2019 | |
| Gilead Sciences, INC. | $16.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payam Aghassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.